Condition
NSCLC (Advanced Non-small Cell Lung Cancer)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 55 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
55 shownOvercoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCNCT07158489 · 2026-08-21
RECRUITINGA Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsNCT07705334 · 2026-06-24
RECRUITINGMicrowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureNCT07528274 · 2026-05-01
RECRUITINGA 2-part Phase 1/2 Open-label Trial on ODM-212NCT07563738 · 2026-03-27
RECRUITINGPulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisNCT07348965 · 2026-03-01
RECRUITINGA Retrospective Real-World Study Based on RATIONALE-307NCT07478809 · 2026-02-28
RECRUITINGA Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationsNCT07361237 · 2025-12-30
RECRUITINGTrilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)NCT06992739 · 2025-12-08
RECRUITINGAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsNCT07371663 · 2025-12-03
RECRUITINGOral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17
RECRUITINGQL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLCNCT07330596 · 2025-10-30
RECRUITINGA Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid TumorsNCT07250386 · 2025-10-13
RECRUITINGA First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091 · 2025-08-18
RECRUITINGObservational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLCNCT07356544 · 2025-08-12
RECRUITINGA Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C MutationNCT06946927 · 2025-06-06
RECRUITINGA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · 2025-05-15
RECRUITINGStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06
RECRUITINGORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIsNCT06775743 · 2025-01-15
RECRUITINGA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsNCT06706076 · 2025-01-09
RECRUITINGFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationNCT06956001 · 2024-11-19
RECRUITINGAI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain MetastasesNCT06604689 · 2024-09-30
RECRUITINGEMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC PatientsNCT07096258 · 2024-06-01
RECRUITINGEffects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung CancerNCT07288632 · 2024-02-09
RECRUITINGPhase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsNCT05856981 · 2023-04-03
RECRUITINGA Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812 · 2026-12-01
NOT_YET_RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07816380 · 2026-10-30
NOT_YET_RECRUITINGConsolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus ChemotherapyNCT07822984 · 2026-10-01
NOT_YET_RECRUITINGGlobal, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyNCT07718737 · 2026-08-28
NOT_YET_RECRUITINGPhase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.NCT07742956 · 2026-08-20
NOT_YET_RECRUITINGAllogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid TumorsNCT07551778 · 2026-08-01
NOT_YET_RECRUITINGBecotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung CancerNCT07627321 · 2026-07-15
NOT_YET_RECRUITINGPhase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.NCT07603791 · 2026-06-30
NOT_YET_RECRUITINGRadiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLCNCT07353476 · 2026-06-01
NOT_YET_RECRUITINGPhase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCNCT07524257 · 2026-05-29
WITHDRAWNGFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung CancerNCT07554859 · 2026-05-20
NOT_YET_RECRUITINGAdebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung CancerNCT07560358 · 2026-05-01
NOT_YET_RECRUITINGSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesNCT07343479 · 2026-05-01
NOT_YET_RECRUITINGA Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）NCT07609251 · 2026-05-01
NOT_YET_RECRUITINGA Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based RegimensNCT07469488 · 2026-04-30
NOT_YET_RECRUITINGFANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung CancerNCT07418866 · 2026-02-01
NOT_YET_RECRUITINGAnlotinib in Cross-line Treatment of NSCLC and SCLCNCT07400575 · 2026-02-01
NOT_YET_RECRUITINGA Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs TreatmentNCT07669051 · 2026-01-01
ACTIVE_NOT_RECRUITINGPredictive Value of Exosomes in Pleural Effusion for Advanced Lung CancerNCT07262671 · 2025-10-16
ACTIVE_NOT_RECRUITINGTracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung CancerNCT06951399 · 2025-09-01
NOT_YET_RECRUITINGImmune-Marker Platform for Patients With Advanced Lung CancerNCT07150598 · 2025-09-01
NOT_YET_RECRUITINGSecond-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLCNCT07703228 · 2025-08-13
ACTIVE_NOT_RECRUITINGPD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 TherapyNCT07014215 · 2025-06-01
NOT_YET_RECRUITINGPhase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid TumorsNCT06652529 · 2025-01-01
NOT_YET_RECRUITINGUniversal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung CancerNCT06653023 · 2024-10-23
SUSPENDEDEfficiency of Contemporary Off-line Adaptive Radiotherapy for Lung CancerNCT07259447 · 2024-06-21
ACTIVE_NOT_RECRUITINGPrognostic Correlation Between the Ratio of the Neutrophil Ratio to the Ratio of CD4+/CD8+ T Cells in Patients With Advanced Non-small Cell Lung Cancer NSCLC) Undergoing Immunotherapy Combined With ChemotherapyNCT06954259 · 2022-07-01
ACTIVE_NOT_RECRUITINGA Retrospective Cohort Analysis of SMARCA4-Deficient Lung CancerNCT07121387 · 2020-01-01
COMPLETEDOsimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain MetastasesNCT07491211 · 2019-07-19
ACTIVE_NOT_RECRUITINGThird-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLCNCT06613633 · 2018-09-01
COMPLETEDStudy of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung CancerNCT01211483 · 2010-09-01
COMPLETEDCommon interventions
docetaxelDRUG4CarboplatinDRUG2CisplatinDRUG2PaclitaxelDRUG2PembrolizumabDRUG2radiotherapyRADIATION2TislelizumabDRUG2adebrelimab,Radiation Therapy,RadiotherapyDRUG1ADU-1805DRUG1After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy.DRUG1Albumin PaclitaxelDRUG1ALK201 for injectionDRUG1ALK202 for injectionDRUG1ALX2004DRUG1AMT-116DRUG1AnlotinibDRUG1Arm B:GFH375DRUG1Arm C:GFH375DRUG1ArmA:GFH375DRUG1AROG4-01DRUG1Becotatug vedotinDRUG1benmelstobart InjectionCOMBINATION_PRODUCT1BevacizumabDRUG1BH-30643DRUG1BH-30643 combo therapy with Carboplatin/PemetrexedDRUG1
Leading sponsors
Fudan University
7
Anhui Provincial Cancer Hospital
3
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2
Shanghai Allink Biotherapeutics Co., Ltd.
2
Shanghai Pulmonary Hospital, Shanghai, China
2
Allist Pharmaceuticals, Inc.
1
ALX Oncology Inc.
1
Aromics Therapeutics
1
Beijing Tide Pharmaceutical Co., Ltd
1
BlossomHill Therapeutics
1
BOE Technology Group Co., Ltd.
1
Daiichi Sankyo
1
Genfleet Therapeutics (Shanghai) Inc.
1
Gruppo Oncologico Italiano di Ricerca Clinica
1
Guangzhou JOYO Pharma Co., Ltd
1
Trial status mix
RECRUITING24
NOT_YET_RECRUITING20
ACTIVE_NOT_RECRUITING6
COMPLETED3
SUSPENDED1
WITHDRAWN1
Phase mix
PHASE225
PHASE113
PHASE36
NA3
EARLY_PHASE11
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.